Angiotensin Receptor Blockers in Aortic Stenosis (ARBAS)

  • End date
    Feb 21, 2025
  • participants needed
  • sponsor
    Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Updated on 21 April 2022
ejection fraction


This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.


Studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore recent studies have shown that renin-angiotensin system medication may slow down aortic stenosis progression rate and left ventricle remodeling.

Thus the present study is a randomized control trial to test the efficacy of the angiotensin receptor blocker (ARB) to slow down aortic stenosis progression and left ventricular remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.

Condition Aortic Stenosis
Treatment Placebo, Angiotensin Receptor Blockers
Clinical Study IdentifierNCT04913870
SponsorInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval
Last Modified on21 April 2022


Yes No Not Sure

Inclusion Criteria

Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and <4m/s)
Normal left ventricular ejection fraction (i.e. ≥50%)
Systolic blood pressure >110 mmHg
Diastolic blood pressure >70 mmHg

Exclusion Criteria

More than mild aortic or mitral regurgitation, or mitral stenosis
Current use or documented indication for renin-angiotensin system medication or Aliskiren
Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
Alzheimer, dementia or known non-compliant patient
Renal dysfunction (glomerular filtration rate <30ml/min/1.73m2)
Chronic hyperkalemia
Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
Newly diagnosed (<2 months) or poorly controlled diabetes
Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (<3 months)
Pregnant or lactating women
Patients unable to read, understand or sign research consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note